Evidence map›Paper›PMID 26491227›Full record

ArticleMediators of inflammation2015

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.

Vladan P Čokić, Olivera Mitrović-Ajtić, Bojana B Beleslin-Čokić, Dragana Marković, Marijana Buač, Miloš Diklić, Nada Kraguljac-Kurtović, Svetozar Damjanović, Pavle Milenković, Mirjana Gotić and 1 more

Open access · goldAbstract read
In one paragraph

Article in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Vladan P ČokićInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Olivera Mitrović-AjtićInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Bojana B Beleslin-ČokićClinic of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, 11000 Belgrade, Serbia.
Dragana MarkovićInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Marijana BuačInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Miloš DiklićInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Nada Kraguljac-KurtovićClinic of Hematology, Clinical Center of Serbia, 11000 Belgrade, Serbia.
Svetozar DamjanovićClinic of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, 11000 Belgrade, Serbia ; Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.
Pavle MilenkovićInstitute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.
Mirjana GotićClinic of Hematology, Clinical Center of Serbia, 11000 Belgrade, Serbia ; Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.
Puri K RajDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
University of Belgrade · RSCentar za Promociju Nauke · RSCenter for Biologics Evaluation and Research · USCenter for Health, Exercise and Sport Sciences · RS

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related genes in circulating CD34(+) cells of MPNs. Regarding laboratory data, leukocytosis has been observed in polycythemia vera (PV) and JAK2V617F mutation positive versus negative primary myelofibrosis (PMF) patients. Moreover, thrombocytosis was reduced by JAK2V617F allele burden in essential thrombocythemia (ET) and PMF. 261 significantly changed genes have been detected in PV, 82 in ET, and 94 genes in PMF. The following JAK-STAT signaling pathway related genes had augmented expression in CD34(+) cells of MPNs: CCND3 and IL23A regardless of JAK2V617F allele burden; CSF3R, IL6ST, and STAT1/2 in ET and PV with JAK2V617F mutation; and AKT2, IFNGR2, PIM1, PTPN11, and STAT3 only in PV. STAT5A gene expression was generally reduced in MPNs. IL-6 cytokine levels were increased in plasma, as well as IL-6 protein levels in bone marrow stroma of MPNs, dependent on JAK2V617F mutation presence in ET and PMF patients. Therefore, the JAK2V617F mutant allele burden participated in inflammation biomarkers induction and related signaling pathways activation in MPNs.

Indexed as

AllelesAntigens, CD34BiomarkersEnzyme-Linked Immunosorbent AssayFemaleHumansImmunohistochemistryInflammationInterleukin-6Janus Kinase 1LeukocytosisMaleMutationMyeloproliferative DisordersOligonucleotide Array Sequence AnalysisPolycythemia VeraAntigens, CD34BiomarkersIL6 protein, humanInterleukin-6JAK1 protein, humanJanus Kinase 1STAT Transcription Factors

Identifiers

PMID26491227
PMCPMC4602333
OpenAlexW1852968885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.